Literature DB >> 12734691

99mTc-MIBI scintigraphy for early detection of locally recurrent non-small cell lung cancer treated with definitive radiation therapy.

Masaya Furuta1, Miwako Nozaki, Miho Kawashima, Mamoru Iimuro, Yoshinori Kitazumi, Aya Okayama, Satoshi Natsui, Yoshio Hamashima, Koushuu Nagao.   

Abstract

After radiation therapy of lung cancer, a dense fibrotic shadow develops in the irradiated lung. Owing to this fibrosis, early detection of local recurrence after treatment is sometimes difficult even when using computed tomography (CT) and magnetic resonance imaging. We investigated the diagnostic accuracy of technetium-99m hexakis 2-methoxyisobutylisonitrile ((99m)Tc-MIBI) scintigraphy for the detection of recurrent lung cancer following definitive radiation therapy. Eighteen patients with primary non-small cell lung cancer treated with radiation therapy 1 year previously were studied with (99m)Tc-MIBI scintigraphy. They showed no evidence of local recurrence on serial chest radiographs. All single-photon emission tomography (SPET) images acquired 2 h after intravenous administration of the radiopharmaceutical were visually interpreted with knowledge of the pretreatment chest radiograph, CT and the details of radiation therapy (radiation portals and administered doses). A region of interest (ROI) analysis was also performed. In addition to the ROI ratio of tumour uptake to accumulation in contralateral normal lung (tumour/lung ratio), another semiquantitative analysis, the ratio of tumour uptake to accumulation in radiation fibrosis (tumour/fibrosis ratio), was performed to differentiate between accumulation in radiation fibrosis and the tumour uptake. The scintigraphic diagnoses were correlated with clinical outcome. The sensitivity, specificity and negative predictive value of (99m)Tc-MIBI scintigraphy for the detection of recurrent lung cancer were all 88.9% (8/9). The tumour/lung ratios (mean+/-SEM) of the nine patients with local recurrence and the other eight without local failure were 2.00+/-0.11 and 1.40+/-0.09, respectively ( P<0.01). The tumour/fibrosis ratios of the patients with and those without recurrence were 1.47+/-0.08 and 0.93+/-0.05, respectively ( P<0.01). These results suggest that (99m)Tc-MIBI scintigraphy might be of value for the detection of recurrent lung cancer, and especially of small foci in areas of radiation fibrosis that are hardly noticeable on serial chest radiographs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734691     DOI: 10.1007/s00259-003-1188-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Comparison of intratumoral distribution of 99mTc-MIBI and deoxyglucose in mouse breast cancer models.

Authors:  H Ohira; K Kubota; N Ohuchi; Y Harada; H Fukuda; S Satomi
Journal:  J Nucl Med       Date:  2000-09       Impact factor: 10.057

2.  Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial.

Authors:  H Palmedo; H J Biersack; S Lastoria; J Maublant; E Prats; H E Stegner; P Bourgeois; R Hustinx; A J Hilson; A Bischof-Delaloye
Journal:  Eur J Nucl Med       Date:  1998-04

3.  Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.

Authors:  T Bury; J L Corhay; B Duysinx; F Daenen; B Ghaye; N Barthelemy; P Rigo; P Bartsch
Journal:  Eur Respir J       Date:  1999-12       Impact factor: 16.671

4.  Detecting recurrent or residual lung cancer with FDG-PET.

Authors:  T Inoue; E E Kim; R Komaki; F C Wong; P Bassa; W H Wong; D J Yang; K Endo; D A Podoloff
Journal:  J Nucl Med       Date:  1995-05       Impact factor: 10.057

5.  The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.

Authors:  R J Hicks; V Kalff; M P MacManus; R E Ware; A F McKenzie; J P Matthews; D L Ball
Journal:  J Nucl Med       Date:  2001-11       Impact factor: 10.057

6.  Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose.

Authors:  J Y Choi; S E Kim; H J Shin; B T Kim; J H Kim
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 7.  Nuclear medicine imaging of lung cancer.

Authors:  S J Goldsmith; L Kostakoglu
Journal:  Radiol Clin North Am       Date:  2000-05       Impact factor: 2.303

8.  Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy.

Authors:  C Soler; P Beauchesne; K Maatougui; T Schmitt; F G Barral; D Michel; F Dubois; J Brunon
Journal:  Eur J Nucl Med       Date:  1998-12

9.  Radiation fibrosis: differentiation from recurrent tumor by MR imaging.

Authors:  H S Glazer; J K Lee; R G Levitt; J P Heiken; D Ling; W G Totty; D M Balfe; B Emani; T H Wasserman; W A Murphy
Journal:  Radiology       Date:  1985-09       Impact factor: 11.105

10.  Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion.

Authors:  T Leitha; C Glaser; M Pruckmayer; M Rasse; W Millesi; S Lang; C Nasel; W Backfrieder; F Kainberger
Journal:  J Nucl Med       Date:  1998-07       Impact factor: 10.057

View more
  1 in total

Review 1.  Diagnostic Performances of 99mTc-Methoxy Isobutyl Isonitrile Scan in Predicting the Malignancy of Lung Lesions: A Meta-Analysis.

Authors:  Shuxin Zhang; Yang Liu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.